Topic
Latest reporting and analysis tagged with Pfizer.
Pfizer announced positive results from a BREAKWATER trial cohort for BRAFTOVI in metastatic colorectal cancer, showing a 64% response rate. The company also received recent analyst ratings.
Pfizer CEO Albert Bourla said at a San Francisco conference that the company is preparing for a consumer obesity drug market similar to Viagra's 1998 launch, with plans for 10 phase 3 studies this year.
Pfizer announced a strategic AI collaboration with Boltz to accelerate drug discovery, after UBS initiated coverage with a Neutral rating citing revenue uncertainty.